The mixed Phase 2 results create uncertainty: primary endpoint failure is negative, but the strong subgroup signal in adolescent irritability with a clean safety profile could support a focused development path. Traders should monitor upcoming FDA interactions and the ZEPHYR schizophrenia readout in August 2026 for further direction on pipeline value.
Price Chart
Executive Summary
MapLight Therapeutics announced topline results from the Phase 2 IRIS trial of ML-004 in autism spectrum disorder. The study missed its primary endpoint in social communication deficits, but a prespecified subgroup of adolescents with moderate-to-severe baseline irritability showed statistically significant and clinically meaningful improvements on both the ABC-I (effect size 1.33, p=0.013) and CGI-I irritability (effect size 1.08, p=0.036) scales. ML-004 was well-tolerated with no severe adverse events and a favorable safety profile versus standard-of-care antipsychotics. The company plans to engage the FDA for an End-of-Phase 2 meeting to discuss a development path for irritability associated with ASD.
Key Facts
- Phase 2 IRIS trial (N=161) did not meet primary endpoint in social communication deficits.
- Prespecified adolescent subgroup with baseline ABC-I ≥16 (N=20) showed ABC-I improvement vs placebo: LS mean difference -9.6, effect size 1.33, nominal p=0.013.
- Same subgroup showed CGI-I irritability improvement: LS mean difference -0.63, effect size 1.08, nominal p=0.036.
- ML-004 was generally well-tolerated; no severe or serious AEs in active arm; no extrapyramidal symptoms; mean weight gain lower than placebo.
- Company expects to engage FDA in End-of-Phase 2 meeting to determine future development path for irritability indication.
- Company remains well capitalized ahead of Phase 2 ZEPHYR trial results for ML-007C-MA in schizophrenia expected by mid-August 2026.
Financial Impact
Not specified
Risk Factors
- Primary endpoint failure may limit overall program value and require confirmatory trials.
- Subgroup analysis based on small sample size (N=20) may not replicate in larger studies.
- Regulatory path for irritability indication is established but requires positive Phase 3 data.
- Upcoming ZEPHYR trial results for ML-007C-MA represent a binary catalyst with potential to overshadow ML-004.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-276691 |
| Document: d31456d8k.htm | 0001193125-26-276691 |
| Document: d31456dex992.htm | 0001193125-26-276691 |
| Document: 0001193125-26-276691-index-headers.html | 0001193125-26-276691 |
| Document: 0001193125-26-276691-index.html | 0001193125-26-276691 |
| Document: 0001193125-26-276691.txt | 0001193125-26-276691 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 11d ago | Insider Cluster | $8.00 | awaiting T+20 | — | $8.17 (−2.13%) |
Oct 15, 2026 12d ago | 144 | $7.70 | awaiting T+20 | — | $8.17 (+6.10%) |
Oct 15, 2026 12d ago | 144 | $7.70 | awaiting T+20 | — | $8.17 (+6.10%) |
Oct 15, 2026 12d ago | 144 | $7.70 | awaiting T+20 | — | $8.17 (+6.10%) |
Sep 24, 2026 4w ago | EFFECT | $10.76 $8.25 | ▼ −23.33% | ▼ −22.91% | $8.17 (−24.07%) |
Sep 18, 2026 5w ago | S-1/A | $10.90 $8.00 | ▼ −26.61% | ▼ −25.70% | $8.17 (−25.05%) |
Aug 4, 2026 11w ago | Insider Cluster | $12.92 $13.06 | ▲ +1.08% | ▲ +1.69% | $8.17 (−36.76%) |
Aug 3, 2026 12w ago | 144 | $12.94 $13.31 | ▲ +2.86% | ▲ +4.10% | $8.17 (−36.86%) |
Jul 30, 2026 12w ago | 144 | $13.02 $12.60 | ▲ +3.23% | ▲ +6.21% | $8.17 (+37.25%) |
Jul 28, 2026 12w ago | Insider Buy | $15.02 $12.86 | ▼ −14.38% | ▼ −19.40% | $8.17 (−45.61%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers